CF PharmTech, Inc. (HKG:2652)

Hong Kong · Delayed Price · Currency is HKD

17.50

+0.01 (0.06%)

Jul 10, 2026, 4:08 PM HKT

Market Cap	7.19B
Revenue (ttm)	481.31M +23.9%
Net Income	2.77M
EPS	0.01
Shares Out	411.03M
PE Ratio	2,601.12
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	155,500
Open	17.88
Previous Close	17.49
Day's Range	17.15 - 17.88
52-Week Range	16.96 - 48.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 26, 2026

About CF PharmTech

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of ... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2007

Employees 540

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2652

Full Company Profile

Financial Performance

In 2025, CF PharmTech's revenue was 432.52 million, a decrease of -28.83% compared to the previous year's 607.75 million. Earnings were 2.49 million, a decrease of -88.22%.

Financial numbers in CNY Financial Statements